Bio-Techne Corporation (TECH)
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?
Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bio-Techne Opens New Customer Experience Centre in Germany
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
TECH Stock Might Rise Following the Leo Shipping Announcement
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Catherine Schulte - Baird Dan Arias - Stifel Conor McNamara - RBC Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management's prepared remarks.
Techne (TECH) Tops Q2 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago.
TECH Gears Up to Report Q2 Earnings: Here's What to Expect
In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.
